

PRESS CLIPPING SHEET

PUBLICATION:	Business Today
DATE:	September-2018
COUNTRY:	Egypt
CIRCULATION:	10,000
TITLE :	Bayer secures approval in the EU for Xarelto.
PAGE:	68
ARTICLE TYPE:	Agency Generated News
REPORTER:	Staff Report
AVE:	1,500

Bayer secures approval in the EU for Xarelto®

The European Commission (EC) has approved a regimen of Xarelto® (rivaroxaban) 2.5 mg twice daily plus acetylsalicylic acid (ASA) 75-100 mg once daily for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk for ischemic events. The first country where Xarelto is planned to become available for these patients is Germany. The EU approval is based on data from the Phase III COMPASS study, which showed that rivaroxaban vascular dose, 2.5 mg twice daily, plus ASA 100 mg once daily reduced the risk of the composite of stroke, cardiovascular death and heart attack by 24% (relative risk reduction) compared with ASA 100 mg once daily alone in patients with CAD or PAD (1).